Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPA1 | O75762 | 4/20 | 0.56 |
| ▸ | PDPK1 | O15530 | 4/20 | 0.55 |
| ▸ | JAK2 | O60674 | 2/20 | 0.55 |
| ▸ | KIF11 | P52732 | 4/20 | 0.54 |
| ▸ | MAP2K4 | P45985 | 2/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.52 |
| ▸ | MAPK6 | Q16659 | 1/20 | 0.52 |
| ▸ | MAPKAPK5 | Q8IW41 | 1/20 | 0.52 |
| ▸ | SGK1 | O00141 | 1/20 | 0.52 |
| ▸ | PLK4 | O00444 | 1/20 | 0.51 |
| ▸ | AURKA | O14965 | 1/20 | 0.51 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.51 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.51 |
| ▸ | EGFR | P00533 | 1/20 | 0.51 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.51 |
| ▸ | LCK | P06239 | 1/20 | 0.51 |
| ▸ | FYN | P06241 | 1/20 | 0.51 |
| ▸ | CSF1R | P07333 | 1/20 | 0.51 |
| ▸ | LYN | P07948 | 1/20 | 0.51 |
| ▸ | KIT | P10721 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12907202 | 0.86 | PDPK1 (0.69) | TRPA1PDPK1JAK2SGK1PLK4 | |
| SCHEMBL2409215 | 0.85 | MAP2K4 (0.58) | TRPA1PDPK1JAK2KIF11MAP2K4 | |
| SCHEMBL12907194 | 0.82 | PDPK1 (0.66) | TRPA1PDPK1JAK2SGK1PLK4 | |
| SCHEMBL84515 | 0.81 | PDPK1 (0.55) | PDPK1JAK2KIF11PLK4AURKA | |
| SCHEMBL25279396 | 0.80 | TRPA1 (0.55) | TRPA1KIF11MAP2K4MAPK1MAPK6 | |
| SCHEMBL13122227 | 0.80 | TRPA1 (0.55) | TRPA1KIF11MAP2K4MAPK1MAPK6 | |
| SCHEMBL1513093 | 0.80 | TRPA1 (0.55) | TRPA1KIF11MAP2K4MAPK1MAPK6 | |
| SCHEMBL30586177 | 0.80 | TRPA1 (0.55) | TRPA1KIF11MAP2K4MAPK1MAPK6 | |
| SCHEMBL30481233 | 0.80 | TRPA1 (0.55) | TRPA1KIF11MAP2K4MAPK1MAPK6 | |
| SCHEMBL10220256 | 0.77 | KIF11 (0.56) | TRPA1KIF11MAP2K4MAPK1MAPK6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101962365-A | Aminoindazole derivatives as protein-kinase inhibitors | AVENTIS PHARMA SA | 2011-02-02 | — | — | CN | claimed |
| CN-1656078-A | Aminoindazole derivatives as protein kinase inhibitors | AVENTIS PHARMA SA (FR) | 2005-08-17 | — | — | CN | claimed |
| US-20040014802-A1 | Aminoindazole derivatives and intermediates, preparation thereof, and pharmaceutical compositions thereof | AVENTIS PHARMA S.A. (FR) | 2004-01-22 | — | — | US | claimed |
| US-RE28939-E | MUSCLE RELAXANTS, ANALGESICS | SMITHKLINE CORPORATION (US) | 1976-08-24 | — | — | US | claimed |
| US-10668071-B2 | (Aza)pyridopyrazolopyrimidinones and indazolopyrimidinones and their use | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2020-06-02 | — | — | US | disclosed |
| EP-3066100-B1 | (AZA)PYRIDOPYRAZOLOPYRIMIDINONES AND INDAZOLOPYRIMIDINONES AS INHIBITORS OF FIBRINOLYSIS | Bayer Pharma AG (DE) | 2019-04-17 | — | — | EP | disclosed |
| US-20180344739-A1 | (AZA)PYRIDOPYRAZOLOPYRIMIDINONES AND INDAZOLOPYRIMIDINONES AND THEIR USE | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2018-12-06 | — | — | US | disclosed |
| US-10098883-B2 | (Aza)pyridopyrazolopyrimidinones and indazolopyrimidinones and their use | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2018-10-16 | — | — | US | disclosed |
| CN-105683194-B | The inhibitor of (azepine) pyrido PyrazolopyrimidinonecGMP and indazole hepyramine as fibrinolysis | 拜耳制药股份公司 | 2018-09-14 | — | — | CN | disclosed |
| US-20170239251-A1 | (AZA)PYRIDOPYRAZOLOPYRIMIDINONES AND INDAZOLOPYRIMIDINONES AND THEIR USE | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-08-24 | — | — | US | disclosed |
| US-9598417-B2 | (Aza)pyridopyrazolopyrimidinones and indazolopyrimidinones and their use | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-03-21 | — | — | US | disclosed |
| EP-3066100-A1 | (AZA)PYRIDOPYRAZOLOPYRIMIDINONES AND INDAZOLOPYRIMIDINONES AS INHIBITORS OF FIBRINOLYSIS | Bayer Pharma Aktiengesellschaft (DE) | 2016-09-14 | — | — | EP | disclosed |
| WO-2007075847-A2 | GLUCOKINASE ACTIVATORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-07-05 | — | — | WO | disclosed |
| US-6949579-B2 | Aminoindazole derivatives and intermediates, preparation thereof, and pharmaceutical compositions thereof | AVENTIS PHARMA S.A. (FR) | 2005-09-27 | — | — | US | disclosed |
| CN-1656078-A | Aminoindazole derivatives as protein kinase inhibitors | AVENTIS PHARMA SA (FR) | 2005-08-17 | — | — | CN | disclosed |
| EP-1487804-A2 | AMINOINDAZOLE DERIVATIVES AS PROTEIN-KINASE INHIBITORS | Aventis Pharma S.A. (FR) | 2004-12-22 | — | — | EP | disclosed |
| US-20040014802-A1 | Aminoindazole derivatives and intermediates, preparation thereof, and pharmaceutical compositions thereof | AVENTIS PHARMA S.A. (FR) | 2004-01-22 | — | — | US | disclosed |
| WO-2003078403-A2 | DERIVES D’AMINOINDAZOLES COMME INHIBITEURS DE PROTEINE-KINASE | AVENTIS PHARMA S.A. (FR) | 2003-09-25 | — | — | WO | disclosed |
| US-4051252-A | ANALGESIC, ANTIINFLAMMATORY, ANTIPYRETIC | BAYER AKTIENGESELLSCHAFT (DT) | 1977-09-27 | — | — | US | disclosed |
| US-RE28939-E | MUSCLE RELAXANTS, ANALGESICS | SMITHKLINE CORPORATION (US) | 1976-08-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040014802-A1 | Aminoindazole derivatives and intermediates, preparation thereof, and pharmaceutical compositions thereof | CYP2C8, NR0B2, NR2C2 | TRPA1 2652/4885PDPK1 4495/4885JAK2 1774/4885 |
| US-20180344739-A1 | (AZA)PYRIDOPYRAZOLOPYRIMIDINONES AND INDAZOLOPYRIMIDINONES AND THEIR USE | SERPINB6, SERPINC1, SERPINE1 | TRPA1 3873/4885PDPK1 1304/4885JAK2 167/4885 |
| US-10668071-B2 | (Aza)pyridopyrazolopyrimidinones and indazolopyrimidinones and their use | SERPINB6, SERPINC1, SERPINE1 | TRPA1 3873/4885PDPK1 1304/4885JAK2 167/4885 |
| US-20170239251-A1 | (AZA)PYRIDOPYRAZOLOPYRIMIDINONES AND INDAZOLOPYRIMIDINONES AND THEIR USE | SERPINB6, SERPINC1, SERPINE1 | TRPA1 3873/4885PDPK1 1304/4885JAK2 167/4885 |
| US-10098883-B2 | (Aza)pyridopyrazolopyrimidinones and indazolopyrimidinones and their use | SERPINB6, SERPINC1, SERPINE1 | TRPA1 3873/4885PDPK1 1304/4885JAK2 167/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.